FRONT ONCOL 润色咨询

Frontiers in Oncology

出版年份:2011 年文章数:14479 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:2.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2024-03-14 Tuo988188 来自广西

    偏重的研究方向:肿瘤
    经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2024-03-14 Stou18389577351 来自广西

    周期两三个月 有问题可以滴滴~

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2024-01-31 mastermaus 来自湖北省

    审稿速度:1.0
    偏重的研究方向:诊断;肿瘤;临床
    经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2024-03-11 第一篇一定要中啊 来自江苏省

    审稿速度:24.0 | 投稿命中率:5.0
    偏重的研究方向:肿瘤
    经验分享:其实是很难的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2024-03-11 Tuo1887878 来自广西

    有办法很快accept 有想法可以联系

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2023-10-30 小鹏友 来自重庆

    审稿速度:3.0 | 投稿命中率:95.0
    偏重的研究方向:肿瘤
    经验分享:非常水……😌😌😌😌

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2021-09-17 146e0980m70暂无昵称

    审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0
    偏重的研究方向:肿瘤
    经验分享:来还愿了
    修回3天后审稿人全部endorse
    第4天就直接accept了
    从投稿到接收差不多两个月左右,这个速度简直感激

    71

    展开71条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2023-04-28 ms1000001631708013 来自浙江省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤;生信
    经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!
    11 Apr 2023 Article accepted for publication.
    07 Apr 2023 Review of Review Editor 3 finalized.
    01 Apr 2023 Review of Review Editor 4 finalized.
    30 Mar 2023 Review of Review Editor 1 finalized.
    17 Mar 2023 Interactive review forum activated.
    07 Feb 2023 submitted manuscript

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2023-08-03 ms3000001338105201 来自广东省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:症状管理;急性白血病
    经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023
    Editorial assignment start date: 13 Jun 2023
    Independent review start date: 19 Jun 2023
    Interactive review activated date: 05 Jul 2023
    Review finalized date: 24 Jul 2023
    Final validation date: 02 Aug 2023
    Manucript accepted: 02 Aug 2023

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2193172, encodeId=4d5021931e208, content=偏重的研究方向:肿瘤<br>经验分享:数度还是蛮快的,三个月内,有办法accept,不懂的可以交流,不碍事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/283133ce76f34249b853d07b3e6c6d71-BFw72jTVyYmR.jpg, createdBy=7c9b9204365, createdName=Tuo988188, createdTime=Thu Mar 14 14:24:32 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2193128, encodeId=828a219312882, content=周期两三个月 有问题可以滴滴~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/21497983ee504933a98597291fbf6bc5-ZZP4hn6SBnAE.jpg, createdBy=6beb9211769, createdName=Stou18389577351, createdTime=Thu Mar 14 10:57:48 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192579, encodeId=b68b21925e9ac, content=有办法很快accept 有想法可以联系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:02:33 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=288, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省)]
    2023-02-13 ms8000000438373883 来自江西省

    收临床case report吗

    3

    展开3条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分